Literature DB >> 19671858

Epigenetic deregulation of DNA repair and its potential for therapy.

Monika E Hegi1, Davide Sciuscio, Anastasia Murat, Marc Levivier, Roger Stupp.   

Abstract

Epigenetic silencing of essential components of DNA repair pathways is a common event in many tumor types, and comprise O6-methylguanine-DNA methyltransferase (MGMT), human mut L homolog 1 (hMLH1), Werner syndrome gene (WRN), breast cancer susceptibility gene 1 (BRCA1), and genes of the Fanconi anemia pathway. Most interestingly, some of these alterations become the Achilles heel of the affected tumors upon treatment with certain classes of anticancer agents. That is, patients whose tumors carry such defects can be stratified for respective therapy rendering some classic DNA damaging agents, such as alkylators or DNA crosslinking agents, into "targeted therapies." Here we review some of the affected repair pathways that, when inactivated, sensitize the tumors to specific drugs and are thus exploitable for individualized therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19671858     DOI: 10.1158/1078-0432.CCR-08-1169

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  26 in total

1.  Extended survival of glioblastoma patients after chemoprotective HSC gene therapy.

Authors:  Jennifer E Adair; Brian C Beard; Grant D Trobridge; Tobias Neff; Jason K Rockhill; Daniel L Silbergeld; Maciej M Mrugala; Hans-Peter Kiem
Journal:  Sci Transl Med       Date:  2012-05-09       Impact factor: 17.956

2.  Pancreatic Adenocarcinoma Associated With Werner's Syndrome (Adult-Onset Progeria).

Authors:  Stephen G Chun; Nelson S Yee; John M Holland; Ralph V Shohet; Melvin P Palalay; Peter K Bryant-Greenwood
Journal:  Gastrointest Cancer Res       Date:  2011-01

3.  Grape seed proanthocyanidins reactivate silenced tumor suppressor genes in human skin cancer cells by targeting epigenetic regulators.

Authors:  Mudit Vaid; Ram Prasad; Tripti Singh; Virginia Jones; Santosh K Katiyar
Journal:  Toxicol Appl Pharmacol       Date:  2012-06-27       Impact factor: 4.219

4.  (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells.

Authors:  Vijayalakshmi Nandakumar; Mudit Vaid; Santosh K Katiyar
Journal:  Carcinogenesis       Date:  2011-01-05       Impact factor: 4.944

Review 5.  O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems.

Authors:  John R Silber; Michael S Bobola; A Blank; Marc C Chamberlain
Journal:  Biochim Biophys Acta       Date:  2012-01-08

6.  Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis.

Authors:  Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Curtis Huttenhower; Noriko Tanaka; Aditi Hazra; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Gastroenterology       Date:  2010-08-02       Impact factor: 22.682

Review 7.  Review of the alterations in DNA methylation in esophageal squamous cell carcinoma.

Authors:  Yoshifumi Baba; Masayuki Watanabe; Hideo Baba
Journal:  Surg Today       Date:  2013-01-05       Impact factor: 2.549

8.  Werner syndrome as a hereditary risk factor for exocrine pancreatic cancer: potential role of WRN in pancreatic tumorigenesis and patient-tailored therapy.

Authors:  Stephen G Chun; Nelson S Yee
Journal:  Cancer Biol Ther       Date:  2010-09-22       Impact factor: 4.742

9.  MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers.

Authors:  Kaori Shima; Teppei Morikawa; Yoshifumi Baba; Katsuhiko Nosho; Maiko Suzuki; Mai Yamauchi; Marika Hayashi; Edward Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Cancer Causes Control       Date:  2010-12-08       Impact factor: 2.506

10.  Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade glioma.

Authors:  Dorothee Hölzl; Georg Hutarew; Barbara Zellinger; Hans U Schlicker; Christoph Schwartz; Peter A Winkler; Karl Sotlar; Theo F J Kraus
Journal:  J Cancer Res Clin Oncol       Date:  2021-05-08       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.